关节炎患者使用TNF抑制剂与神经炎症事件风险:丹麦和瑞典协作人群队列研究
该研究基于瑞典和丹麦全国风湿病注册数据,纳入类风湿关节炎(RA)、银屑病关节炎(PsA)和强直性脊柱炎(AS)患者,比较TNF抑制剂暴露与非暴露者神经炎症疾病发生风险。结果显示AS/PsA患者使用TNF抑制剂与神经炎症疾病风险增加相关,而RA患者未见风险增加,绝对风险低于每1000患者年1例。
要点
- AS/PsA患者使用TNF抑制剂与神经炎症疾病风险增加相关,RA患者未见此关联。
- TNF抑制剂治疗患者的神经炎症疾病绝对风险低于每1000患者年1例。
- 多发性硬化的风险模式与总体神经炎症疾病相似。
核心结论
- 在AS/PsA患者中,使用TNF抑制剂与神经炎症疾病发生风险增加相关,但在RA患者中未观察到该关联。
- 尽管风险增加,TNF抑制剂治疗患者的神经炎症疾病绝对风险低于每1000患者年1例。
研究设计与样本
- 通过前瞻性链接国家患者登记获取脱髓鞘疾病和炎症性神经病诊断信息,采用Cox比例风险模型按疾病和国家比较TNF抑制剂暴露与非暴露者的HR和95%CI。
主要发现
- 多发性硬化的HR模式与所有类型神经炎症疾病合并分析相似。
临床怎么用
- 对AS/PsA患者启动TNF抑制剂治疗时,应关注神经炎症疾病的监测,尤其在多发性硬化相关症状出现时。
- RA患者使用TNF抑制剂时神经炎症疾病风险未见增加,但仍需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether tumour necrosis factor alpha inhibitors (TNFis) are associated with an increased risk of neuroinflammatory diseases among patients with arthritic diseases. METHODS: Cohorts of patients with rheumatoid arthritis (RA, n=25 796), psoriatic arthritis (PsA, n=8586) and ankylosing spondylitis (AS, n=9527) who initiated a TNFi treatment year 2000-2017 were identified from nationwide clinical rheumatology registers in Sweden and Denmark. Information on demyelinating disease and inflammatory neuropathy diagnoses was retrieved from prospective linkage to National Patients Register. A Cox proportional hazard model was used to estimate HRs and 95% CI comparing TNFi exposed and non-exposed, by disease and country. RESULTS: Among 111 455 patients with RA, we identified 270 (Sweden) and 51 (Denmark) events (all types of neuroinflammatory diseases combined), corresponding to crude incidence rates (per 1000 person-years) of 0.37 (Sweden) and 0.39 (Denmark) in TNFi-treated patients vs 0.39 (Sweden) and 0.28 (Denmark) in unexposed patients, and an age-sex-calendar-period-adjusted HR (95% CI) of 0.97 (0.72 to 1.33) (Sweden) and 1.45 (0.74 to 2.81) (Denmark) in TNFi exposed compared with non-exposed patients. For a total of 64 065 AS/PsA patients, the corresponding numbers were: 196 and 32 events, crude incidence rates of 0.59 and 0.87 in TNFi-treated patients vs 0.40 and 0.19 in unexposed patients, and HRs of 1.50 (1.07 to 2.11) and 3.41 (1.30 to 8.96), for Sweden and Denmark, respectively. For multiple sclerosis, the patterns of HRs were similar. CONCLUSIONS: Use of TNFi in AS/PsA, but not in RA, was associated with increased risk of incident neuroinflammatory disease, though the absolute risk was below one in 1000 patients/year.
引用
- Kopp TI, Delcoigne B, Arkema EV, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis. 2020. PMID: 32161058. doi:10.1136/annrheumdis-2019-216693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。